ASH 2021 | Autologous stem cell transplant for POEMS Syndrome
In this video, Ankit Kansagra, MD, UT Southwestern Medical Center, Simmons Comprehensive Cancer Center, Dallas, TX, outlines some of the important aims and results from a retrospective analysis evaluating the use of autologous stem cell transplant (ASCT) for patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes (POEMS) syndrome. Dr Kansagra explains four main reasons why this analysis was important, including how the data will help researchers better understand the safety, benefits, side effects, and long-term survival outcomes of patients undergoing ASCT for POEMS. This interview took place at the 63rd ASH Annual Meeting and Exposition, Atlanta, 2021.
Disclosures
Medical Advisory Board: Abbvie, Alynylam, BMS, Cota Health, GSK, Janssen, Oncopeptide, Takeda
